Titan Pharmaceuticals, Inc.(TTNP)Earnings, Financials & Key Ratios
TTNP•NASDAQ
$3.08
Price updated Jul 2, 2026
AboutTitan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.Show more
- Revenue$0-100.0%
- EBITDA-$5M+36.5%
- Net Income-$5M+15.5%
- EPS (Diluted)-5.23+29.4%
- ROE-103.63%+25.5%
TTNP Price & Volume
Titan Pharmaceuticals, Inc. (TTNP) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Absence Signals Terminal Liquidity Risk
Investment Thesis • Updated 2025Q2
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity insolvency risk
Key Thesis Takeaways
- Titan Pharmaceuticals currently operates as a pre-revenue entity with no clear path to commercial viability, as evidenced by the complete cessation of product sales and a cumulative retained earnings deficit of $397.8 million.
- The firm's reliance on external capital to fund ongoing SG&A expenses of $657,000 per quarter creates a high probability of terminal dilution for existing shareholders.
- Investors should remain cautious as the lack of tangible assets and persistent negative cash flows suggest an imminent requirement for dilutive financing to maintain basic corporate operations.
Verdict Logic
the company's limited cash position of $2.8 million against ongoing quarterly losses of $689,000 suggests an unsustainable runway that necessitates immediate and potentially dilutive capital intervention.
TTNP Growth Metrics
Titan Pharmaceuticals, Inc. (TTNP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-88.24%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM48.64%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM54.15%
Return on Capital
10 Years-143.02%
5 Years-187.53%
3 Years-194.61%
Last Year-100.35%
Peers Comparison
Key metrics vs top competitors for Titan Pharmaceuticals, Inc. (TTNP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.08 | $4.1M | -0.59 | -100% | — | -103.63% | — | |
| $73.15 | $1.43B | -7.52 | -43.89% | -284.18% | -87% | — | |
| $7.32 | $432.37M | 49.31 | -3.63% | 3.72% | 4.11% | — | |
| $4.57 | $187.03M | 3.05 | — | — | 55.42% | — | |
| $21.64 | $2.1B | -42.43 | 504.79% | -0.11% | -0.33% | — | |
| $37.47 | $1.22B | 21.66 | 23.62% | 9.41% | 26.74% | — |
Compare TTNP vs Peers
Titan Pharmaceuticals, Inc. (TTNP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when TTNP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TTNP Frequently Asked Questions
Titan Pharmaceuticals, Inc. (TTNP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Titan Pharmaceuticals, Inc.'s revenue?
Titan Pharmaceuticals, Inc. (TTNP) reported $0.0M in revenue for fiscal year 2024. This represents a 90% decrease from $0.1M in 1995.
How fast is Titan Pharmaceuticals, Inc. growing?
Titan Pharmaceuticals, Inc. (TTNP) saw revenue decline by 100.0% over the past year.
Is TTNP profitable?
Titan Pharmaceuticals, Inc. (TTNP) reported a net loss of $2.8M for fiscal year 2024.
Dividend & Returns
What is TTNP's return on equity?
Titan Pharmaceuticals, Inc. (TTNP) has a return on equity (ROE) of -103.6%. Negative ROE indicates the company is unprofitable.
What is Titan Pharmaceuticals, Inc.'s free cash flow?
Titan Pharmaceuticals, Inc. (TTNP) had negative free cash flow of $2.7M in fiscal year 2024, likely due to heavy capital investments.